Tadalafil CAS NO 171596-29-5 Inquire about Tadalafil

Tecoland supplies Tadalafil bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Tadalafil is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Tadalafil?

Tadalafil is a PDE5 inhibitor marketed in pill form for treating erectile dysfunction (ED), and for the treatment of pulmonary arterial hypertension. In October 2011 the U.S. Food and Drug Administration (FDA) approved tadalafil for treating the signs and symptoms of benign prostatic hyperplasia (BPH) as well as a combination of BPH and erectile dysfunction when the conditions coincide.

On November 21, 2003 the FDA approved tadalafil for sale in the United States as the third ED prescription drug pill (after sildenafil and vardenafil). Like sildenafil and vardenafil, tadalafil is recommended as an ‘as needed’ medication. Tadalafil is the only one of the three that is also offered as a once-daily medication. Moreover, tadalafil was approved in May 2009 in the United States for the treatment of pulmonary arterial hypertension and is under regulatory review in other regions for this condition.

Side Effects

The most common side effects when using tadalafil are headache, stomach discomfort or pain, indigestion, burping, acid reflux, back pain, muscle aches, flushing, and stuffy or runny nose. These side effects reflect the ability of PDE5 inhibition to cause vasodilation (cause blood vessels to widen), and usually go away after a few hours.

Mechanism of action

Tadalafil, sildenafil, and vardenafil all act by inhibiting the PDE5 enzyme. These drugs also inhibit other PDE enzymes. Tadalafil inhibits PDE11 more than sildenafil or vardenafil. PDE11 is expressed in skeletal muscle, the prostate, the liver, the kidney, the pituitary gland, and the testes. The effects on the body of inhibiting PDE11 are not known.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.